BC008-1A (Bispecific)

About REMD Biotherapeutics

REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.

Therapeutic Areas